United States securities and exchange commission logo





                            October 28, 2022

       Gerald E. Quirk, Esq.
       Chief Legal Officer
       Syros Pharmaceuticals, Inc.
       35 Cambridge Park Drive, 4th Floor
       Cambridge, MA 02140

                                                        Re: Syros
Pharmaceuticals, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed October 14,
2022
                                                            File No. 333-267888

       Dear Gerald E. Quirk:

              We have limited our review of your registration statement to
those issues we have
       addressed in our comments. In some of our comments, we may ask you to
provide us with
       information so we may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-3 filed October 14, 2022

       General

   1.                                                   We note that you filed
a current report on Form 8-K on September 16, 2022 in connection
                                                        with the completion of
your acquisition of Tyme Technologies, Inc., and that this 8-K is
                                                        incorporated by
reference into your registration statement on Form S-3. You indicated in
                                                        that Form 8-K that the
financial statements of the acquired business and pro forma
                                                        financial information
required by Item 9.01(a) and (b) of Form 8-K would be filed by
                                                        amendment within 71
days. Please note that we will not be a position to accelerate the
                                                        effective date of this
registration statement until you have filed the required financial
                                                        statements and pro
forma financial information. Refer to the Instruction to Item 9.01 of
                                                        Form 8-K. It also
appears that such incorporation by reference would require that an
                                                        auditors' consent be
provided for the incorporation by reference into this registration
 Gerald E. Quirk, Esq.
Syros Pharmaceuticals, Inc.
October 28, 2022
Page 2
      statement of the auditor   s report with respect to the consolidated
financial statements of
      Tyme Technologies, Inc. included in the Annual Report on Form 10-K for
the year ended
      March 31, 2022 and that a consent should be filed for the incorporation
by reference of
      such auditor   s report into any previously filed Securities Act
registration statement. See
      the Exhibits Table in Item 601(a) of Regulation S-K and footnote 5
thereto. Please revise
      your filings or advise, as appropriate.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Lauren Hamill at 303-844-1008 or Tim Buchmiller at
202-551-3635 with
any questions.



                                                           Sincerely,
FirstName LastNameGerald E. Quirk, Esq.
                                                           Division of
Corporation Finance
Comapany NameSyros Pharmaceuticals, Inc.
                                                           Office of Life
Sciences
October 28, 2022 Page 2
cc:       Cynthia T. Mazareas, Esq.
FirstName LastName